Breakthrough Therapies Act
This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.